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Abstract
Background: Clotrimazole is an antifungal imidazole derivative showing anti- neoplastic effect in some tumors, but its
anticancer potential is still unclear in oral squamous cell carcinoma (OSCC). The aim of this study was to evaluate the
antitumor effect of clotrimazole, and to investigate the possible mechanism of clotrimazole-mediated antitumor activity in
OSCC.
Methodology: In vitro experiments, the cell viability and clonogenic ability of three human OSCC cell lines CAL27, SCC25
and UM1 were detected after clotrimazole treatment by CCK8 assay and colony formation assay. Cell cycle progression and
apoptosis were assessed by flow cytometry, and the involvement of several mediators of apoptosis was examined by
western blot analysis. Then, the in vivo antitumor effect of clotrimazole was investigated in CAL27 xenograft model.
Immunohistochemistry and western blot analysis were performed to determine the presence of apoptotic cells and the
expression of Bcl-2 and Bax in tumors from mice treated with or without clotrimazole.
Results: Clotrimazole inhibited proliferation in all three OSCC cell lines in a dose-and time-dependent manner, and
significantly reduced the colony formation of OSCC cells in vitro. Clotrimazole caused cell cycle arrest at the G0/G1 phase. In
addition, clotrimazole induced apoptosis in OSCC cells, and significantly down-regulated the anti-apoptotic protein Bcl-2
and up-regulated the pro-apoptotic protein Bax. Notably, clotrimazole treatment inhibited OSCC tumor growth and cell
proliferation in CAL27 xenograft model. Clotrimazole also markedly reduced Bcl-2 expression and increased the protein level
of Bax in tumor tissues of xenograft model.
Conclusion: Our findings demonstrated a potent anticancer effect of clotrimazole by inducing cell cycle arrest and cellular
apoptosis in OSCC.
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Introduction
Clotrimazole is an antifungal imidazole derivative which has
been used in clinic for more than 20 years. Since the early 1980s,
clotrimazole has been available for the treatment of oral
candidiasis, skin infections, and for prophylaxis of oropharyngeal
candidiasis in immunocompromised patients [1,2]. In addition to
its antifungal properties, a few studies have shown its anticancer
properties. Clotrimazole had growth inhibition effects on several
human cancer cell lines, such as lung carcinoma, colorectal cancer,
breast cancer and endometrial cancer [3–6]. Clotrimazole also
inhibited tumor growth in xenograft rat model of intracranial
gliomas (C6 and 9L) and prolonged the rat survival [7].
Previous study showed that clotrimazole, as calmodulin
antagonist, inhibited the proliferation of human cancer cells via
disrupting cellular Ca2+ homeostasis. It released Ca2+ from
intracellular stores while inhibiting Ca2+ influx and blocking IK
channels [8,9]. Further studies demonstrated that clotrimazole
blocked cell cycle in G1 phrase and induced apoptosis [10–12].
Moreover, clotrimazole effectively decreased glucose consumption
and energy metabolism by inhibiting glycolysis and ATP
production, and then led to reduction of tumor cell viability
[13,14]. However, these previous studies about the anticancer
effects and mechanisms of clotrimazole were mostly involved in
adenocarcinomas. The effects of clotrimazole on squamous cell
carcinoma (SCC) remain relatively unknown. Squamous cell
carcinoma and adenocarcinoma are different histological types,
which is one of the most important reasons for the different patient
responses to the same anticancer treatment [15]. Thus, it is
necessary and interesting to investigate the effects of clotrimazole
on squamous cell carcinoma, such as oral squamous cell
carcinoma (OSCC).
OSCC is the most common oral malignancy, representing up to
80–90% of all malignant neoplasms of the oral cavity [16]. The 5-
year survival rate of OSCC patients has not improved significantly
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in the last several decades [17]. Therefore, it is necessary to
identify novel and effective therapeutic agents for the treatment of
OSCC. Whether clotrimazole directly affects the proliferation of
OSCC cells has not been reported. Thus, the present study was
designed to demonstrate the antitumor effects of clotrimazole on
OSCC cells and to investigate the possible underlying mecha-
nisms. We observed that clotrimazole significantly inhibited
OSCC cell proliferation both in vitro and in vivo. Moreover,
clotrimazole induced cell apoptosis and led to a significant down-
regulation of anti-apoptotic protein Bcl-2 and up-regulation of
pro-apoptotic protein Bax.
Materials and Methods
Cell lines and Materials
Three human oral squmous cell carcinoma cell lines (CAL27,
SCC25 and UM1) were included in this study. CAL27 (ATCC
number: CRL-2095) and SCC25 (ATCC number: CRL-1628)
were purchased from the American Type Culture Collection
(ATCC, Manassas, VA, USA). UM1 cell line was a gift from
Professor Hongzhang Huang (Department of Oral and Maxillo-
facial Surgery, Guanghua School of Stomatology, Sun Yat-sen
University, China). SCC25 and UM1 cells were cultured in 1:1
mix of Dulbecco’s Modified Eagle Medium and Ham F12
medium (DMEM/F12) (Invitrogen, Carlsbad, CA, USA) supple-
mented with penicillin (100 units/ml), streptomycin (100 mg/ml)
and 10% (v/v) fetal bovine serum (FBS) (GIBCO, Grand Island,
NY, USA). CAL27 cells were cultured in DMEM supplemented
with the same concentrations of FBS and penicillin and
streptomycin. Cells were incubated at 37uC in a humidified
atmosphere of 5% CO2.
Clotrimazole was purchased from Sigma Chemical (St. Louis,
MO, USA) and dissolved in dimethyl sulfoxide (DMSO) (Sigma
Chemical). The concentration of DMSO was kept under 0.1%
throughout all the experiments to avoid cytotoxicity. Antibodies
against Bcl2, Bax, cleave-caspase3 and alpha-tublin were pur-
chased from Cell Signaling Technology (Beverly, MA, USA).
PCNA antibody was purchased from Fuzhou maxim (Fuzhou,
China).
CCK8 cell viability assay
Cell viability was assessed by a Cell counting Kit-8 (CCK8)
assay (Dojindo, Kumamoto, Japan). OSCC cells (56103 cells/well)
were plated into 96-well plates. After 24 h, the cells were treated
with different concentrations of clotrimazole (0–80 mM) or DMSO
(0.1%). After incubation with clotrimazole for 24 h, 48 h or 72 h,
the CCK8 reagent was added to each well and cells were
incubated for 2 h at 37uC. The absorbance (optical density) at
450 nm was measured.
Cell colony formation assay
OSCC cells were seeded into 6-well plates in triplicate at a
density of 1000 cells/well in 2 ml of medium containing 10% FBS.
After 24 h, cultured cells were replaced with fresh culture medium
containing DMSO or various concentrations of clotrimazole (10,
20 or 30 mM) at 37uC and 5% CO2. Cells were grown for 14 days.
The culture medium was changed once every other day. The cell
colonies were stained for 20 minutes with a solution containing
0.5% crystal violet and 25% methanol, followed by three rinses
with tap water to remove excess dye. Colonies consisting of .50
cells were counted under a microscopy. All experiments were
repeated in triplicate and the average values are presented.
Cell cycle analysis
OSCC cells (26105 cells/well) were seeded in 6-well plates.
After starvation with basal medium for 24 h, cells were treated
with DMSO or clotrimazole (30 and 40 mM) for 24 h and then
harvested by trypsinization. The cells were fixed with cold 70%
ethanol and stained for total DNA content with RNase A and
propidium iodide staining buffer (BD, San Diego, CA, USA)
according to the manufacturer’s instructions. A minimum of
10,000 cells were acquired per sample and cell cycle distribution
was analyzed using a flow cytometer (Becton Dickinson, San Jose,
CA, USA) and ModFit software V3.0 (Verity Software House,
Topsham, ME, USA).
Apoptosis analysis
Cell apoptosis was assessed using the Annexin V-FITC/
Propidium Iodide (PI) double-staining apoptosis detection kit
(KeyGen, China). OSCC cells were treated with DMSO or
clotrimazole (30 and 40 mM) for 24 h. The cells were collected and
stained according to the manufacturer’s instructions. The apop-
tosis data acquisition and analysis was performed by a FACS
Calibur flow cytometer. Basal apoptosis were identically deter-
mined on control cells.
Western blot analysis
OSCC cells (26105 cells/well) were seeded in 6-well plates.
After 24 h, the medium was replaced with fresh culture medium
containing 40 mM clotrimazole or DMSO for 12, 24 and 48 h.
Then cultured cells were lysed in RIPA buffer supplemented with
protease and phosphatase inhibitors (Pierce, Rockford, IL, USA).
The protein concentrations were measured using a BCA protein
assay kit (Pierce, Rockford, IL, USA). Samples (40 mg/lane) were
incubated at 100uC for 5 min, separated on 12% (w/v) SDS-
PAGE gels, and electrophoretically transferred to a PVDF
membrane (Millipore, Billerica, Massachusetts, USA). The blotted
membrane was blocked with 5% non-fat milk for 2 h at room
temperature. The membrane was incubated with primary
antibodies against alpha-tublin, Bcl-2 and Bax overnight at 4uC,
and then incubated with goat anti-mouse secondary antibody or
goat anti-rabbit secondary antibody. The immunoreactive bands
were detected using an enhanced chemiluminescence(ECL)detec-
tion system (Pierce, Rockford, IL, USA). Quantification of bands
was performed using the gel analysis submenu of Image J software.
Xenograft model analysis
Animal experiments were carried out in strict accordance with
the recommendations in the guide for the care and use of
laboratory animals. The protocol was approved by the Committee
on the Ethics of Animal Experiments of the Sun Yat-sen
University, China (Permit Number: 00054610). All surgery was
performed under chloral hydrate anesthesia, and all efforts were
made to minimize suffering. We purchased twenty-four female
BALB/c nude mice (4 weeks old; 14–16 g) from the Animal Care
Unit of Guangdong. The animals were bred in the Animal Care
Unit of Sun Yet-sun University (Guangzhou, China) which
provides specific pathogen-free conditions. Each mouse was
inoculated with CAL27 cells (56106 cells per animal) subcutane-
ously into the back next to the right front limb. Ten days later, the
xenografts were identifiable as a mass of more than 6 mm in
maximal diameter in all recipients. Then mice were randomly
assigned into control and treated groups (n = 12/group). The
clotrimazole-treated group was injected 6 times a week intraper-
itoneally (i.p.) at 150 mg/kg/body per day for two weeks, whereas
the control group received peanut oil (200 ml as vehicle). During
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this period, all the mice were examined every day to assess their
health and any evidence of drug toxicity. Tumors were measured
every two days with a standard caliper and tumor volumes were
calculated as follows: tumor volume (mm3) = [tumor length (mm)
6tumor width (mm) 2]/2. Body weight of the mice was also
recorded. At the end of the experiments (following treatment), the
animals were anesthetized. Tumors were weighed after being
separated from the surrounding muscles and dermis. For each
group, tumor tissues were collected and separated into two parts.
One was fixed with 10% neutral formalin and embedded in
paraffin for immunohistochemistry examination, and the other
aliquot were homogenized into tumor lysis buffer for western blot
analysis.
Immunohistochemistry
Immunohistochemistry was performed on xenograft tumor
tissues. Antigen retrieval was performed by heating these tissue
sections in 10 mmol/L citric acid buffer (pH 6.0) for 20 min.
Tissue sections were blocked in 5% normal goat serum for 30 min,
and incubated in 3% hydrogen peroxide to suppress endogenous
peroxidase activity. Sections were then incubated with PCNA
antibody (1:100) and cleaved caspase-3 antibody (1:1000) at 4uC
overnight, followed by peroxidase-conjugated goat anti-rabbit
secondary antibody for 1 h at room temperature. Finally, slides
were treated with chromogen diaminobenzidine (DAB) (Dako,
Carpinteria, CA, USA) for antigen detection and counterstained
with hematoxylin. All sections were examined under light
microscopy at 6200 magnification. For each section examined,
cells in five randomly selected fields were counted. PCNA labeling
index and cleaved caspase-3 labeling index was calculated as the
percentage of positive cells over total number of cells examined.
Statistical analysis
The data were presented as means 6 standard deviation of at
least three independent experiments. Statistical analysis of the
results was performed using a two-tailed Student’s t-test or one-
way ANOVA and post hoc multiple comparison test with SPSS
16.0 software (IBM, Armonk, New York, USA). P value,0.05
were considered statistically significant.
Results
Clotrimazole inhibits human OSCC cells viability and
reduces colony formation in vitro
To investigate the effects of clotrimazole on human OSCC cells
growth in vitro, three OSCC cell lines CAL27, SCC25 and UM1
were used in our study. Treatment with clotrimazole led to
significant inhibition of the cell viability in a dose-and time-
dependent manner at each concentration (20, 30, 40 and 50 mM)
compared with control cells (P,0.05, respectively) in these OSCC
cell lines (Fig.1). After 40 mM clotrimazole treatment for 48 h, the
inhibition rate reached 53.1% in CAL27 cells, 43.8% in SCC25
cells, and 61.5% in UM1 cells. The IC50 values for 48 h of
clotrimazole treatment were 35.9 mM, 35.6 mM, and 31.4 mM in
CAL27, SCC25, and UM1 cells, respectively. Therefore, we used
30 mM and 40 mM clotrimazole that encompassed concentrations
above and below IC50 values for further experiments. Next, the
ability of these three cell lines to form colonies with or without
clotrimazole treatment was examined for a period of two weeks.
Figure 1. Clotrimazole inhibits OSCC cells proliferation. OSCC cells (CAL27, SCC25, and UM1) were treated with clotrimazole (0–80 mM) for
24 h, 48 h and 72 h, and cell viability was detected using a Cell Counting Kit-8 assay. The results presented as mean 6 standard deviation values for
three independent experiments.
doi:10.1371/journal.pone.0098885.g001
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Clotrimazole markedly decreased cell colony formation in a dose-
dependent manner (Fig. 2A). At the low concentration of 10 mM,
clotrimazole inhibited cell colony formation of CAL27, SCC25
and UM1 cells by 54.2%, 54.1% and 54.4%, respectively (P,
0.05). Additionally, at the concentration of 30 mM clotrimazole,
cell colony formation was strongly reduced by 95.0%, 95.5% and
93.0%, respectively (P,0.001), as compared with the respective
control groups (Fig.2B). Collectively, our results indicated that
clotrimazole inhibited the growth of OSCC cells in vitro.
Clotrimazole induces OSCC cells cycle arrest
The possible effect of clotrimazole on cell cycle progression in
OSCC cells was assessed by flow cytometry. Cells were treated
with clotrimazole (0, 30 and 40 mM) for 24 h. Clotrimazole
induced cell cycle arrest in a dose-dependent manner (Fig.3, P,
0.05). Clotrimazole (40 mM) treatment significantly increased the
proportion of OSCC cells in the G0/G1 phase, compared to the
respective control cells (92.761.3% vs. 77.860.3% in CAL27,
P=0.002; 90.960.5% vs. 71.761.3% in SCC25, P,0.001;
87.460.4% vs.58.460.3% in UM1, P,0.001, respectively).
Clotrimazole (40 mM) treatment also decreased the percentage of
cells in the S phase of OSCC cell lines compared to the respective
control cells (6.861.3% vs. 14.660.2% in CAL27, P=0.023;
8.861.1% vs. 25.860.9% in SCC25, P,0.001; 7.161.1%
vs.28.761.6% in UM1, P=0.046, respectively).
Clotrimazole induces apoptosis of OSCC cells
To further investigate whether clotrimazole initiates cellular
apoptosis, OSCC cells were incubated with clotrimazole (0, 30,
and 40 mM) for 24 h and analyzed by flow cytometry. The
percentages of OSCC cells undergoing early apoptosis and late
apoptosis were increased by clotrimazole treatment in a concen-
tration-dependent manner (P,0.05) (Fig.4). The percentage of
cells undergoing apoptosis was determined by the sum of cells in
early and late apoptosis. Clotrimazole (40 mM) induced a
significant increase in the proportion of apoptotic cells in
CAL27, SCC25 and UM1 cells (12.360.9% vs. 2.060.1%,
12.661.1% vs. 1.960.1%, and 13.061.9% vs. 1.760.3%,
respectively). The mechanisms underlying the apoptosis-inducing
effect of clotrimazole in OSCC cells were assessed by western blot
analysis. The levels of apoptosis-related proteins such as anti-
apoptotic protein Bcl-2 and pro-apoptotic protein Bax were
examined in total protein from tumor cells treated with DMSO or
clotrimazole(40 mM) for 12 h, 24 h and 48 h. Our results showed
that treatment with clotrimazole for 48 h induced a 3.3-fold and
Figure 2. Clotrimazole inhibits colony formation of OSCC cells.
OSCC cells (CAL27, SCC25, and UM1) grown in 6-well plates (1000 cells/
well) were incubated with various concentrations of clotrimazole (0, 10,
20 and 30 mM) for two weeks. Cell colonies were stained and counted as
described in the Methods section. The results presented as mean 6
standard deviation values for three independent experiments. *P,0.05;
**P,0.01 compared with solvent control.
doi:10.1371/journal.pone.0098885.g002
Figure 3. Clotrimazole induces G0/G1 cell cycle arrest in OSCC
cells. OSCC cells were exposed to various concentrations of
clotrimazole (0, 30 and 40 mM) for 24 h. Cell cycle distributions were
analyzed by flow cytometry with PI staining. *P,0.05, **P,0.01 as
compared with the CAL27 control cells;# P,0.01 as compared with the
SCC25 control cells; `P,0.01 as compared with the UM1 control cells.
doi:10.1371/journal.pone.0098885.g003
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Figure 4. Clotrimazole induces apoptosis of OSCC cells. CAL27, SCC25 and UM1 cells were incubated with various concentrations of
clotrimazole (0, 30 and 40 mM) for 24 h and labeled with Annexin V and propidium iodide (PI). (A) Apoptosis of OSCC cells was analyzed by flow
cytometry. The bottom right quadrant represents the percentage of early apoptotic cells (Annexin V+/PI2), whereas the top right quadrant is the
percentage of late apoptotic cells (Annexin V+/PI+). (B) Percentages of cells in apoptosis at each clotrimazole concentration. The results are presented
as the mean of three similar experiments. *P,0.05; **P,0.01 compared with solvent control.
doi:10.1371/journal.pone.0098885.g004
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1.6-fold decrease of Bcl2 protein expression in CAL27 and UM1
cells, respectively, as compared with respective control cells.
Conversely, clotrimazole treatment induced a 2.3-fold and 1.6-fold
increase of Bax protein expression in CAL27 and UM1 cells,
respectively (Fig.5). These results indicate that an apoptotic
mechanism is implicated in the clotrimazole-induced growth-
inhibitory effects in OSCC cells.
Clotrimazole inhibits OSCC tumor growth in vivo
To evaluate whether clotrimazole affects tumor growth in vivo,
the CAL27 cell line was selected for the establishment of the
OSCC xenograft nude mouse model. Ten days later, the mice
were randomly assigned into control and treated groups. The
tumor volume (mean6SD) was 52.762.1 mm3 in control group
and 51.762.3 mm3 in clotrimazole-treated group. Then clotri-
mazole was injected intraperitoneally at a dose of 150 mg/kg/day
6 days a week for two weeks. During the 14 days of drug or vehicle
treatments, all the mice appeared to be healthy and there was no
obvious sign or symptom of drug toxicity. The animal weight was
not significantly different between the groups at any time point
(Fig. S1). There are no obvious abnormalities were detected upon
gross observation of the heart, liver, spleen, kidney, and
gastrointestinal tract in clotrimazole-treated animals (Fig. S2).
Consistent with our in vitro results, intraperitoneal administration
of clotrimazole strikingly decreased the tumor volume of CAL27
cell xenograft in nude mice by 57.9% (P=0.042, Fig.6A,B), and
the mean weights of the excised tumors were approximately 53.6%
lower in clotrimazole-treated mice than in control mice (P=0.035,
Fig.6C). The proliferation rates of tumor cell were assessed in situ
by PCNA antigen labeling index. Our findings showed that
clotrimazole treatment decreased tumor cell proliferation (Fig.6D).
Clotrimazole induces apoptosis in OSCC xenograft model
To determine whether clotrimazole affects the apoptosis of
tumor cells in vivo, we further analyzed the apoptotic tumor cells
and the expressions of Bcl-2 and Bax in xenograft tumors by
Immunohistochemistry and western blot analysis, respectively.
Our results showed that clotrimazole increased the number of
apoptotic tumor cells in treated mice tissue compared with control
mice (Fig. 6E). Moreover, clotrimazole treatment induced a 1.5-
fold decrease of Bcl2 expression and 2.0-fold increase of Bax level
compared to the control mice (Fig.5). These results indicated that,
similar to the results in vitro, clotrimazole decreased tumor growth
in vivo through the induction of cell apoptosis.
Discussion
Clotrimazole is an important imidazole-derived antimycotic
agent that is clinically safe and readily tolerated by human.
Recently, clotrimazole was found to possess antitumor activity
against several types of cancer cells in vitro [4,9,18,19]. However,
the histological types of these solid tumors that have been
investigated for clotrimazole were all adenocarcinomas. There is
little report about the anticancer effects of clotrimazole on SCC,
which is one of the largest subset of cancer. Adenocarcinoma and
SCC can show tremendous differences in their presenting
symptoms, natural histories, prognosis, and responses to therapy
[20]. Hence, we selected oral squamous cell carcinoma as the
representative one of SCC to assess the anticancer effect of
clotrimazole. OSCC is the most common type of head and neck
squamous cell carcinoma, which is the sixth most common cancer
worldwide [21]. Despite evolution in management, the prognosis
and survival of OSCC patients is still poor. Thus, the identification
of novel and effective therapeutic agents to inhibit OSCC cell
growth is essential. In the current study, we demonstrated that
clotrimazole exerted potent anticancer effect on human OSCC
cells both in vitro and in vivo. Moreover, the inhibitory action of
clotrimazole was correlated with the induction of cell cycle arrest
and apoptosis in OSCC.
Published data have shown that clotrimazole reduces the
viability of several types of cancer cells [3,5,6]. However, there
is little evidence for the effect of clotrimazole on human OSCC
cells. Thus, in the initial vitro study, we measured the growth
inhibitory effect of clotrimazole in OSCC cells. We found that
clotrimazole decreased cells viability and reduced colony forma-
tion of OSCC cells in a dose-dependent manner. The effective
doses of clotrimazole (30 mM and 40 mM) used in our in vitro
study were similar to those used in prior studies on breast cancer,
endometrial cancer, and glioblastoma [4,6,12]. Our subsequent in
vivo experiment further revealed that clotrimazole markedly
inhibited cell proliferation and slowed the tumor growth of
OSCC. Khalid et al reported that clotrimazole treatment caused a
significant inhibition of intracranial tumor growth in rat vivo
model of glioma [7]. Taken together, our experimental data show
that clotrimazole can exert significant growth inhibitory effects on
human OSCC cells, similar to the effects reported in human
adenocarcinoma cells.
In order to mechanistically explain our observations, we
investigated the effect of clotrimazole treatment on cell cycle and
apoptosis. We found that clotrimazole blocked OSCC cycle
progression at the G0/G1 phase in vitro experiment. This result is
consistent with previous studies, such as glioblastoma and lung
cancer [10,22]. Liu et al observed that clotrimazole arrested cell
cycle at G0/G1 phase correlating with the overexpression of
p27Kip and the decrease of cyclin D1 [12]. Furthermore, our
results demonstrated that clotrimazole significantly induced
Figure 5. Clotrimazole regulates apoptotic protein levels in
OSCC cells and tumor tissue. (A) CAL27 and UM1 cells were treated
with 40 mM clotrimazole or DMSO for 12 h, 24 h, and 48 h. The
expression of the anti-apoptotic protein Bcl-2 and the pro-apoptotic
protein Bax was assessed by western blot. (B) The apoptosis-related
protein expressions in tumors from control mice and clotrimazole-
treated mice (150 mg/kg) were also analyzed by western blot analysis.
Clotrimazole treatment decreased the expression of Bcl-2 and increased
the level of Bax in clotrimazole-treated tumors compared with control
animals. Data shows the representative of three independent experi-
ments. Quantification of bands was performed using Image J software
and the relative ratio was calculated by the density.
doi:10.1371/journal.pone.0098885.g005
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apoptosis in OSCC cell lines which was further proven by our in
vivo experiment. Several previous in vitro investigations indicated
clotrimazole induced cell apoptosis in other types of cancer cells.
Khalid and colleagues observed that clotrimazole sensitized cells to
cisplatin by induction of apoptosis in human glioblastoma cell
[10]. Meira et al. displayed the marked nuclear condensation and
f-actin depolymerization after clotrimazole treatment in MCF-7
breast cancer cells [18]. Ito et al. demonstrated that clotrimazole
induced depletion of intracellular Ca2+ stores and led to cell
apoptosis in acute lymphoblastic leukemia cells [11]. Obviously,
clotrimazole can inhibit the growth of OSCC in vitro and in vivo
by cell cycle arrest and induction of cellular apoptosis. Our results
disclosed that the clotrimazole-induced apoptosis parallel to the
significant up-regulation of the pro-apoptotic protein Bax, the
down-regulation of the anti-apoptotic protein Bcl-2, and activation
of caspase-3. It is well known that the Bcl-2 family members play a
central role in regulating apoptosis and dictating cell fate through
an accurate balance between pro-apoptotic (Bax, Bak, and BH3-
only proteins) and anti-apoptotic (Bcl-2 and its closest homologues)
factors [23]. When the ratio of Bax to Bcl-2 increases, the
mitochondrial permeability transition pore opens and in turn
results in releasing apoptogenic mitochondrial proteins to activate
Figure 6. Clotrimazole slows the growth of human OSCC xenograft tumors in nude mice. A total of 56106 CAL27 cells/mouse were
injected subcutaneously into the back next to the right front limb. When a tumor became palpable, clotrimazole (150 mg/kg/body) was administered
intraperitoneally for 2 weeks, 6 times per week, control mice treated with equal volume of peanut oil. (A) Representative photographs of the gross
tumors from nude mice treated with clotrimazole or peanut oil. (B) Graphs represent the average tumor volumes of CAL27 xenografts in mice from
the control and clotrimazole-treated groups. (C) Graphs represent the average weight of tumors from the control and clotrimazole-treated groups.
(D) PCNA expression in tumor tissues was assessed by IHC. The bar graph shows PCNA labeling index (PCI) in twelve tumors per each experimental
group. PCI (%) = positive tumor cells/total tumor cells6100%. (E) Cleaved caspase-3 expression in tumor tissues was assessed by IHC. The bar graph
shows cleaved caspase-3 labeling index (CI) in twelve tumors per each experimental group. CI (%) = positive tumor cells/total tumor cells6100%.
*P,0.05; ** P,0.01 compared with control nude mice.
doi:10.1371/journal.pone.0098885.g006
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caspases and induce cell apoptosis [24]. However, several previous
studies have not connected the anticancer effects of clotrimazole
with this apoptotic pathway. For example, the in vitro study by
Horng et al. showed that clotrimazole significantly induced Ca2+
release from endoplasmic reticulum and also triggered apoptosis in
human hepatoma cells in Ca2+-independent manner [25].
Therefore, to the best of our knowledge, it is the first time to
report the involvement of Bcl2 family in clotrimazole-mediated
apoptosis of SCC cells. Certainly, a lot of work is needed to
confirm the activation of the apoptotic pathway which is regulated
by BCL2 family of proteins as the universal mechanism of
inhibitory action of clotrimazole in our further study.
In prior in vivo studies, the dosages of clotrimazole were ranged
from 100 to 160 mg/kg/day for various time periods. In most of
these studies, there was no major adverse reaction or significant
change in blood or hepatic parameters [26–28]. Khalid et al.
demonstrated that 125 mg/kg/day clotrimazole administered by
intraperitoneal injection significantly inhibited intracranial glioma
tumor formation and prolonged rat survival without sign or
symptom of drug toxicity [7]. The doses of 150 mg/kg clotrima-
zole used in our study were similar to these reported in previous
literature. We found that 150 mg/kg clotrimazole significantly
inhibited OSCC tumor growth without any macroscopic evidence
of abnormal changes in the heart, liver, spleen, kidney, stomach,
and intestine. This finding was of particular importance as it was
the first time that clotrimazole was shown to inhibit OSCC tumor
growth in vivo. Moreover, these results provide a foundation for
our further animal model experiments that utilizes clotrimazole to
improve treatment outcomes in OSCC, such as the 4-nitroquino-
line 1-oxide (4NQO)-induced mice tongue carcinogenesis model,
which closely mimics multistage carcinogenesis of human OSCC
on morphological and biological concepts [29].
Conclusions
In summary, our results revealed that clotrimazole inhibited
OSCC cell proliferation and tumor growth in vitro and in vivo,
possibly by suppressing the apoptosis-related molecules. These
results suggest that clotrimazole could be a potential therapeutic
agent to block the progression of OSCC. Our results provide
evidence for future clinical strategies that utilize clotrimazole as a
single agent or adjuvant chemotherapeutic reagents to improve
treatment outcomes in OSCC.
Supporting Information
Figure S1 Clotrimazole treatment does not affect body
weight of OSCC xenografted nude mice. A total of 56106
CAL27 cells/mouse were injected subcutaneously into the back
next to the right front limb. When a tumor became palpable,
clotrimazole (150 mg/kg/body) was administered intraperitoneal-
ly for 2 weeks, 6 times per week, control mice treated with equal
volume of peanut oil. The body weight of xenografted nude mice
(n = 12) was measured every two days for Fourteen days, and
means of the body weight of each group were presented by mean
6 (SD). Statistical significance was determined by Student t-test
when compared with the control. P.0.05.
(TIF)
Figure S2 The gross observation of the organs and
histopathology of OSCC xenograft. (A) The gross observa-
tion of the heart, liver, spleen, kidney, and gastrointestinal tract in
control and clotrimazole-treated mice. (B) The histopathology of
OSCC xenograft stained by hematoxylin and eosin in control and
clotrimazole-treated mice. Original magnifications, 6200. Bar:
50 mM.
(TIF)
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